List of Excipients in Branded Drug BREXPIPRAZOLE

« Back to Dashboard

Generic Drugs Containing BREXPIPRAZOLE

Company	Ingredient	NDC	Excipient
Ajanta Pharma USA Inc	brexpiprazole	27241-204	CELLULOSE, MICROCRYSTALLINE
Ajanta Pharma USA Inc	brexpiprazole	27241-204	FERRIC OXIDE RED
Ajanta Pharma USA Inc	brexpiprazole	27241-204	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in BREXPIPRAZOLE?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
3	FERRIC OXIDE RED
2	FERRIC OXIDE YELLOW

Brexpiprazole Excipient Strategy and Commercial Opportunities

Last updated: October 8, 2026

Brexpiprazole has a relatively simple marketed oral formulation, creating commercial room for differentiated excipient systems rather than a broad reformulation platform. The strongest opportunities are improved dissolution, orally disintegrating delivery, liquid dosing for patients with swallowing or adherence barriers, pediatric-friendly products, and formulation patents that extend protection beyond the core compound estate. Rexulti is marketed by Otsuka in the United States under a collaboration with Lundbeck and is approved for schizophrenia, adjunctive treatment of major depressive disorder, and agitation associated with dementia due to Alzheimer’s disease.[1,2]

What excipients are used in Rexulti tablets?

Rexulti tablets use conventional solid-dose excipients designed for manufacturability, tablet integrity, disintegration and lubrication. The FDA prescribing information identifies the principal inactive ingredients as lactose monohydrate, corn starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose and magnesium stearate.[1]

Excipient	Primary formulation role	Commercial relevance
Lactose monohydrate	Diluent and tablet-bulk agent	Low cost; creates opportunities for lactose-free or lower-lactose alternatives
Corn starch	Diluent and disintegrant	Supports tablet breakup but can be replaced by higher-performance superdisintegrants
Microcrystalline cellulose	Compression aid and diluent	Supports direct compression and mechanical strength
Low-substituted hydroxypropyl cellulose	Disintegrant and binder	Useful in immediate-release tablet processing
Magnesium stearate	Lubricant	Controls ejection force; excessive use can slow wetting and dissolution

The current formulation is suitable for a conventional immediate-release tablet. Its composition does not, based on the public label, indicate a complex amorphous solid dispersion, lipid system, modified-release matrix or controlled-release technology.[1]

Why is excipient selection commercially important for brexpiprazole?

Brexpiprazole is a poorly water-soluble antipsychotic compound. For such compounds, excipient selection affects wetting, particle dispersion, dissolution rate, dose uniformity and exposure consistency. These factors become more important when a product is designed for lower doses, liquid administration, rapid disintegration or use by patients with dysphagia.

The commercial value of excipient innovation depends on whether it solves a defined clinical or manufacturing problem:

1. Improved dissolution can reduce formulation variability and support a more robust generic product.
2. Orally disintegrating tablets can address swallowing difficulty and improve administration in psychiatric and geriatric populations.
3. Liquid formulations can support titration, institutional use and patients who cannot swallow tablets.
4. Taste-masked dispersions can make pediatric or geriatric administration more practical.
5. Excipient systems that improve powder flow or content uniformity can reduce manufacturing losses at low strengths.

The opportunity is strongest where the formulation produces a measurable pharmacokinetic, usability or manufacturing benefit. A simple substitution of one filler for another is less likely to support meaningful patent protection.

What formulation problems should an excipient strategy solve?

Dissolution and wetting

Brexpiprazole formulation development should prioritize rapid and reproducible wetting. Candidate approaches include:

• Sodium lauryl sulfate or other low-level surfactants.
• Poloxamers and related wetting agents.
• Copovidone or povidone as polymeric solubilizers.
• Crospovidone, croscarmellose sodium or sodium starch glycolate as higher-performance disintegrants.
• Spray-dried or co-processed excipients that improve drug dispersion.
• Amorphous solid dispersions using hypromellose acetate succinate, hypromellose or polyvinyl alcohol.

Surfactant use must be controlled because excessive levels can affect gastrointestinal tolerability, tablet strength and dissolution reproducibility. Polymer-based systems may offer better intellectual-property differentiation but require stronger control of moisture, residual solvent and physical stability.

Low-dose content uniformity

Rexulti is marketed in low strengths, including 0.25 mg and 0.5 mg presentations.[1] Low-dose products create a content-uniformity problem because the active pharmaceutical ingredient may represent a small fraction of tablet mass. Excipient systems that improve ordered mixing, adhesive carrier distribution or granule uniformity can have direct manufacturing value.

Potential solutions include:

• Co-processed microcrystalline cellulose and mannitol.
• Spray-dried carrier particles.
• Carrier-based ordered mixtures.
• Wet granulation with controlled binder addition.
• Drug layering onto inert spheres or excipient granules.
• Continuous manufacturing with in-line blend monitoring.

A formulation patent should connect the excipient architecture to a measurable result, such as reduced content-uniformity variability, faster dissolution or improved stability.

Tablet disintegration

The marketed excipient system relies on corn starch and low-substituted hydroxypropyl cellulose. A next-generation immediate-release tablet could use a superdisintegrant system to reduce disintegration time without increasing friability.

A commercially relevant formulation would need to balance:

• Disintegration time.
• Hardness and friability.
• Magnesium stearate sensitivity.
• Moisture uptake.
• Blend segregation.
• Dissolution at different pH conditions.
• Tablet size at the lowest strengths.

Crospovidone is attractive for rapid wicking and low gel formation. Croscarmellose sodium can provide strong swelling but may be more sensitive to formulation level and compression conditions. A dual-disintegrant system may support a stronger formulation claim if the combination produces an unexpected result.

What orally disintegrating tablet opportunities exist for brexpiprazole?

An orally disintegrating tablet is one of the clearest commercial opportunities. Patients treated with antipsychotics may have dysphagia, poor cooperation, cognitive impairment or difficulty managing conventional tablets. These issues are relevant to older adults with Alzheimer’s disease-related agitation and to institutional care settings.

A brexpiprazole ODT could use:

• Mannitol for mouthfeel and rapid dissolution.
• Crospovidone or low-substituted hydroxypropyl cellulose for disintegration.
• Sucralose, acesulfame potassium or other sweeteners for taste correction.
• Flavor systems compatible with brexpiprazole’s sensory profile.
• Colloidal silicon dioxide for flow improvement.
• Magnesium stearate or sodium stearyl fumarate for lubrication.

The product would need strong taste masking. Brexpiprazole’s low dose helps because the total active mass is small, but low dose does not eliminate the need for palatability testing. Direct compression is attractive for speed and cost, while freeze-drying can produce faster disintegration but increases manufacturing cost and packaging requirements.

A proprietary ODT could support a 505(b)(2) strategy if it offers a clinically meaningful administration advantage over the tablet. A generic ODT would ordinarily face the requirements applicable to the selected dosage form and reference product, including comparative performance and, where required, bioequivalence evidence.[3]

What liquid formulation opportunities exist?

A ready-to-use oral solution or suspension could expand use in hospitals, long-term-care facilities and patients unable to swallow tablets. The main technical barrier is brexpiprazole’s limited aqueous solubility.

Possible approaches include:

• Cosolvent systems using polyethylene glycol or propylene glycol.
• Surfactant-stabilized suspensions.
• Cyclodextrin complexation.
• pH adjustment where compatible with stability and tolerability.
• Nanocrystal or nanosuspension technology.
• Polymer-stabilized microparticles.
• Dry powders for reconstitution.

A true solution is commercially simpler for dosing accuracy but may require substantial solubilization excipients. A suspension can reduce solubilizer load but requires control of sedimentation, redispersibility, particle-size distribution and dose withdrawal accuracy.

For Alzheimer’s-related agitation, an oral liquid could have practical value in supervised administration. The product would need a conservative excipient profile because geriatric patients may be sensitive to alcohol, propylene glycol, high osmolarity and gastrointestinal irritants.

How can excipient patents extend brexpiprazole exclusivity?

Excipient patents can protect a formulation after the composition-of-matter patent expires, but their enforceability depends on claim scope, evidence of unexpected performance and the extent to which a generic product practices the claims.

Potential claim categories include:

Claim category	Example protected subject matter	Strategic value
Immediate-release composition	Brexpiprazole plus defined disintegrant, surfactant or polymer ratio	Supports product-specific formulation protection
ODT	Mannitol, superdisintegrant, taste-masking agent and compression profile	Targets a distinct dosage form
Liquid formulation	Solubilizer, pH range, suspension stabilizer or redispersibility specification	May support 505(b)(2) competition
Solid dispersion	Brexpiprazole dispersed in a specified polymer matrix	Can address dissolution and physical stability
Manufacturing process	Granulation, milling, coating or blending conditions	Creates process barriers but may be difficult to detect
Particle engineering	Nanocrystals, defined particle size or surface treatment	May improve dissolution and support platform licensing
Stability	Low-degradation formulation under defined storage conditions	Useful where the formulation solves a real shelf-life problem

The core brexpiprazole compound patent is commonly identified as U.S. Patent No. 7,888,362, with an Orange Book expiration listed in 2027.[4] The Orange Book must be reviewed for the current patent and exclusivity entries because listed patents, pediatric extensions, delistings and litigation certifications can affect generic timing.

A formulation patent should not rely solely on the presence of a familiar excipient. Stronger claims usually tie composition to a functional result, such as a specified dissolution profile, improved stability, reduced impurity formation, or a clinically relevant administration advantage.

What is the FDA regulatory status of brexpiprazole?

Brexpiprazole is FDA-approved as Rexulti tablets for:

• Schizophrenia in adults.
• Adjunctive treatment of major depressive disorder in adults.
• Agitation associated with dementia due to Alzheimer’s disease.[1,2]

The product is regulated as a small-molecule drug, not a biologic. Biosimilar pathways therefore do not apply. Competition will occur through ANDAs, 505(b)(2) applications and conventional branded lifecycle products.

A new excipient should be assessed against FDA’s inactive-ingredient framework, including prior use in the relevant route, dosage form and dose range. Novel excipients may require additional toxicology and chemistry, manufacturing and controls data. FDA’s Inactive Ingredient Database can help determine whether a proposed excipient has precedent in oral products, but precedent in another route does not eliminate formulation-specific regulatory review.[5]

What generic entry risks exist for Rexulti?

Generic entry risk has three main components:

1. Paragraph IV challenges to listed patents.
2. Paragraph III certifications that defer launch until patent expiry.
3. Non-infringing formulations that avoid specific formulation claims.

For an immediate-release tablet, the core compound patent is the principal timing barrier. Generic applicants may also evaluate crystalline-form, formulation, process and method-of-use patents listed in the Orange Book. Method-of-use patents can be relevant where FDA labeling includes protected indications, although a generic applicant may seek a label that omits the patented use.

The most likely initial generic launch scenario is a conventional immediate-release tablet that uses a different excipient system while matching the reference product’s bioequivalence requirements. ODT, oral-liquid and specialty formulations create separate opportunities for branded or 505(b)(2) competition.

Which companies are positioned to compete with brexpiprazole?

Otsuka and Lundbeck control the principal branded commercial position through Rexulti.[2,6] Generic competition is expected from companies with established CNS portfolios and ANDA capabilities, including large U.S., Indian and European generic manufacturers. The commercial attractiveness of entry depends on patent certification, settlement terms, manufacturing readiness and the ability to obtain approval for multiple strengths.

Potential competitors fall into four groups:

Competitor type	Product strategy	Main advantage
Conventional ANDA filer	Immediate-release tablets	Lowest development complexity
Specialty generic company	ODT or liquid	Differentiated administration
505(b)(2) developer	New dosage form or delivery system	May obtain labeling and formulation differentiation
Excipient or CDMO partner	Solubility, particle engineering or taste masking	Enables licensing and co-development

Publicly disclosed licensing and collaboration arrangements between Otsuka and Lundbeck are central to the branded product’s commercial history.[6] Excipient companies can enter through technology licenses, formulation development agreements, contract manufacturing or supply arrangements rather than by launching an independent brexpiprazole product.

How strong is the brexpiprazole formulation opportunity?

The formulation opportunity is moderate to strong, but it is concentrated in differentiated dosage forms rather than routine tablet substitution.

Strongest opportunities

• ODT for swallowing difficulty and supervised administration.
• Oral suspension or solution for geriatric and institutional use.
• Amorphous or nanocrystal systems that produce a clear dissolution benefit.
• Low-dose manufacturing systems that improve content uniformity.
• Taste-masked products with pediatric or geriatric positioning.
• Excipient platforms that reduce tablet size or improve dose flexibility.

Weaker opportunities

• Replacing lactose with another standard filler without a performance advantage.
• Minor lubricant or binder substitutions.
• Routine colorant changes.
• Formulations that improve laboratory dissolution but do not improve bioavailability, stability or administration.

What commercial metrics should investors monitor?

The most relevant indicators are:

• Orange Book patent listings and expiration dates.
• FDA ANDA approvals for brexpiprazole tablets.
• Paragraph IV litigation and settlement dates.
• Otsuka and Lundbeck Rexulti sales disclosures.
• Prescribing growth in Alzheimer’s-related agitation.
• Development of ODT, liquid or long-acting products.
• FDA inactive-ingredient precedent for proposed excipient systems.
• Manufacturing scale-up and supply agreements.
• Changes in payer coverage after generic approval.

Rexulti’s expansion into Alzheimer’s-related agitation broadens the addressable population but also increases the value of administration-friendly products. A low-volume specialty formulation can be commercially viable if it captures institutional, geriatric or adherence-sensitive use without requiring a full replacement of the branded tablet.

Key Takeaways

• Rexulti uses a conventional oral-tablet excipient system based on lactose, corn starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose and magnesium stearate.
• Brexpiprazole’s low aqueous solubility makes wetting, dissolution and particle engineering important formulation targets.
• ODT and liquid formulations offer the clearest commercial differentiation.
• Low-dose strengths create opportunities for excipient systems that improve content uniformity and manufacturing control.
• The core compound patent is commonly listed as U.S. Patent No. 7,888,362, with expiration in 2027 according to Orange Book records.
• Excipient patents are strongest when tied to measurable performance, stability or administration benefits.
• Generic competition will most likely begin with conventional immediate-release tablets, while 505(b)(2) products can pursue liquid, ODT or other differentiated dosage forms.
• Biosimilar risk does not apply because brexpiprazole is a small-molecule drug.

FAQs

Can brexpiprazole be formulated as an orally disintegrating tablet?

Yes. A brexpiprazole ODT could use mannitol, crospovidone, taste-masking agents and direct-compression technology. The main development risks are palatability, friability, moisture sensitivity and bioequivalence.

Which excipients are most useful for improving brexpiprazole dissolution?

Surfactants, polymeric solubilizers, superdisintegrants, cyclodextrins, nanocrystal stabilizers and amorphous-solid-dispersion polymers are the main technical options. Selection depends on stability, dose, manufacturing method and target dosage form.

Is a brexpiprazole oral liquid commercially attractive?

Yes, particularly for long-term-care, geriatric and dysphagia populations. A suspension may be more practical than a true solution because of brexpiprazole’s limited water solubility.

Can an excipient patent block a brexpiprazole generic?

It can create an additional infringement risk if the generic product practices valid, enforceable claims. A generic manufacturer may avoid the patent by using a different excipient system or manufacturing process.

Does brexpiprazole have biosimilar competition?

No. Brexpiprazole is a small-molecule drug. Competition will occur through ANDA generics, 505(b)(2) products and branded reformulations rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2023). Rexulti (brexpiprazole) prescribing information.
2. U.S. Food and Drug Administration. (2023). FDA approves brexpiprazole for agitation associated with dementia due to Alzheimer’s disease.
3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
4. U.S. Patent No. 7,888,362. (2011). Quinoline derivative. United States Patent and Trademark Office.
5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
6. H. Lundbeck A/S. (2011). Lundbeck and Otsuka enter into collaboration agreement for aripiprazole successor brexpiprazole.